(Q44790997)

6 December 2017

title

A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration (English)

1 reference

6 December 2017

6

Christer Halldin

1 reference

6 December 2017

7

Lars Farde

1 reference

6 December 2017

Mirjam Talvik

1

1 reference

6 December 2017

Anna-Lena Nordström

2

1 reference

6 December 2017

Niels-Erik Larsen

3

1 reference

6 December 2017

Aurelija Jucaite

4

1 reference

6 December 2017

Simon Cervenka

5

1 reference

6 December 2017

publication date

6 March 2004

1 reference

6 December 2017

number of pages

6

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

6 December 2017

volume

175

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

148-153

1 reference

Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-004-1802-1

Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain

21 January 2018

1 reference

12 December 2020

The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.

1 reference

12 December 2020

Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients

1 reference

12 December 2020

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1 reference

12 December 2020

D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

1 reference

12 December 2020

Plasma level monitoring of antipsychotic drugs. Clinical utility

1 reference

12 December 2020

High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET.

1 reference

12 December 2020

D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients

1 reference

12 December 2020

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

12 December 2020

The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics.

1 reference

12 December 2020

Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia

1 reference

12 December 2020

Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.

1 reference

12 December 2020

Dose-response relationships of perphenazine in the treatment of acute psychoses

1 reference

12 December 2020

A rating scale for drug-induced akathisia

1 reference

12 December 2020

Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks

1 reference

12 December 2020

Stereoselective binding of 11C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET.

1 reference

12 December 2020

Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride

1 reference

12 December 2020

The ECAT EXACT HR: performance of a new high resolution positron scanner.

1 reference

12 December 2020

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

1 reference

12 December 2020

In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans

1 reference

12 December 2020

Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients

1 reference

12 December 2020

Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis

1 reference

12 December 2020

Binding of phenothiazine neuroleptics to plasma proteins

1 reference

12 December 2020

Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients

1 reference

12 December 2020

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

1 reference

12 December 2020

Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol

1 reference

12 December 2020

Head fixation device for reproducible position alignment in transmission CT and positron emission tomography

1 reference

12 December 2020

Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment

1 reference

12 December 2020

Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

1 reference

12 December 2020

D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

1 reference

12 December 2020

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

12 December 2020

Simplified reference tissue model for PET receptor studies.

1 reference

12 December 2020

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

1 reference

12 December 2020

Binding study of sulfonylureas and phenothiazines to bovine serum albumin using difference spectrophotometry

1 reference

12 December 2020

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

1 reference

12 December 2020

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

12 December 2020

Drug therapy. Binding of drugs to serum albumin (second of two parts)

1 reference

12 December 2020

Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man

1 reference

12 December 2020

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study

1 reference

12 December 2020

The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs

1 reference

12 December 2020

Neuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels

1 reference

12 December 2020

Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels

1 reference

12 December 2020

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

1 reference

12 December 2020

Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients

1 reference

12 December 2020

Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure.

1 reference

12 December 2020

A high-performance liquid chromatographic method for the assay of perphenazine and its dealkylated metabolite in serum after therapeutic doses

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Binding of drugs to serum albumin (first of two parts)

1 reference

12 December 2020

10.1007/S00213-004-1802-1

Identifiers

DOI

1 reference

6 December 2017

1 reference